Lombard raises up to $3.9 million:
This article was originally published in Clinica
Executive Summary
UK company Lombard Medical has raised up to £2.5m ($3.9m), with a £2m pledged by private equity firm Camden Partners. The US equity firm may also subscribe to a further £300,000, Lombard says. The company is aiming the funds at developing cardiovascular products, a market which was estimated at £13bn in 2001. The market is forecast to grow to £20.4bn in 2004, the London-based company says. "I am delighted to be able to announce the success of the fund raising achieved in a very difficult market where many companies were postponing or cancelling their fundraising activities," said Alistair Taylor, Lombard's chairman.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.